IDENTIFIKASI GEJALA PASCA VAKSINASI COVID-19 DOSIS KE-3 (BOOSTER) PADA MAHASISWA S1 KEPERAWATAN

Suyatno Hadi Saputro; Reza Nuraini

doi:10.30651/jkm.v8i3.25877

Penulis

Suyatno Hadi Saputro Universitas Muhammadiyah Surabaya
Reza Nuraini Universitas Muhammadiyah Surabaya

DOI:

https://doi.org/10.30651/jkm.v8i3.25877

Kata Kunci:

COVID-19 Vaccine Booster Dose, AEFI

Abstrak

Objective: To find out the symptoms of Post-Immunization Adverse Events (AEFI) that appear in the third Dose of COVID-19 (Booster) vaccination for nursing undergraduate students.

Methods: This research design uses a quantitative descriptive research design, a population of 211, and a sample of 138 using a purposive sampling technique, the variable in this study is Post-Immunization Adverse Events (AEFI) of the third Dose of COVID-19 Vaccine (Booster). Using analytical descriptive data analysis.

Results: Symptoms of AEFI that often appear after booster doses of AstraZeneca, Moderna, Pfizer, and Sinovac vaccinations are headache, fever, pain accompanied by weakness in the injected arm. Respondents who received the Moderna vaccine dominated symptoms of AEFI.

Conclusion: It is hoped that this research can provide information on how to properly describe, prevent and manage AEFI symptoms

Referensi

Andrzejczak-Grządko, S., Czudy, Z., & Donderska, M. (2021). Side effects after COVID-19 vaccinations among residents of Poland. European Review for Medical and Pharmacological Sciences, 25(12), 4418–4421. https://doi.org/10.26355/eurrev_202106_26153

Buleleng, B. P. B. D. K. (2022). VAKSINASI BOOSTER. https://bpbd.bulelengkab.go.id/informasi/detail/artikel/11_vaksinasi-booster

Chansaenroj, J., Suntronwong, N., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., & Thatsanatorn, T. (2022). Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the.

Kemenkes RI Dirjen P2P. (2021). Keputusan Direktur Jenderal Pencegahan dan Pengendalian Penyakit Nomor Hk.02.02/4/1/2021 tentang Petunjuk Teknis Pelaksanaan Vaksinasi dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (COVID-19). Kementerian Kesehatan RI, 4247608(021), 114. https://www.kemkes.go.id/article/view/19093000001/penyakit-jantung-penyebab-kematian-terbanyak-ke-2-di-indonesia.html

Kementerian Kesehatan Republik Indonesia. (2020). FAQ. https://www.kemkes.go.id/folder/view/full-content/structure-faq.html

Kementerian Kesehatan Republik Indonesia. (2021). Kejadian Ikutan Paska Imunisasi (KIPI) Pada Vaksinasi COVID-19. https://www.balaibaturaja.litbang.kemkes.go.id/read-kejadian-ikutan-paska-imunisasi-kipi-pada-vaksinasi-covid19

Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3

Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., … Hardy, A. (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised t. The Lancet Infectious Diseases, 22, 1131–1141. https://doi.org/10.1016/s1473-3099(22)00271-7

Ponticelli, D., Madotto, F., Conti, S., Antonazzo, I. C., Vitale, A., Della Ragione, G., Romano, M. L., Borrelli, M., Schiavone, B., Polosa, R., Ferrara, P., & Mantovani, L. G. (2022). Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Internal and Emergency Medicine, 17(2), 481–486. https://doi.org/10.1007/s11739-021-02857-y

Supangat, Sakinah, E. N., Nugraha, M. Y., Qodar, T. S., Mulyono, B. W., & Tohari, A. I. (2021). COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia. BMC Pharmacology and Toxicology, 22(1), 1–7. https://doi.org/10.1186/s40360-021-00528-4

Yulyani, V., Hasbie, N. F., Farich, A., & Valentine, A. (2022). Hubungan Status Demografi, Komorbid Dengan KIPI Post Vaksin COVID-19 Pada Tenaga Kesehatan. Jurnal Ilmiah Kesehatan Sandi Husada, 11, 153–160. https://doi.org/10.35816/jiskh.v11i1.725